MARS: mutation-adjusted risk score for advanced systemic mastocytosis
2 Visualizzazioni
• 07/09/23
0
0
Incorporare
administrator
Iscritti
Andreas Reiter, MD, University Medical Centre, Mannheim, Germany, discusses how a mutation-adjusted risk score (MARS) may improve treatment stratification for advanced systemic mastocytosis (AdvSM). This interview took place at the Myeloproliferative Neoplasms Advances Day 2019 in London, UK.
Mostra di più
Commenti su Facebook
SORT BY-
I migliori commenti
-
Ultimi commenti